Intra-Cellular Therapies (ITCI) Stock Analysis

What Intra-Cellular Therapies does

Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.

Key metrics

ETFs linked to ITCI

Broad-market and Healthcare sector ETFs an investor holding Intra-Cellular Therapies is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ITCI fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Intra-Cellular Therapies?

Intra-Cellular Therapies trades under the ticker ITCI on NASDAQ.

Which exchange is ITCI listed on?

ITCI is listed on NASDAQ.

What sector does Intra-Cellular Therapies operate in?

Intra-Cellular Therapies is classified in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).

How can PortView help analyze ITCI in a portfolio?

PortView shows ITCI's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.